Close

Ligand Pharma (LGND) Says Retrophin (RTRX) Presented Sparsentan Phase 2 Study Data

September 7, 2016 9:26 AM EDT Send to a Friend
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) partner Retrophin, Inc. (Nasdaq: RTRX) announced positive top-line results from the Phase 2 DUET study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login